AgeneBio Receives NIH Grant to Initiate Phase 3 HOPE4MCI Trial to Treat MCI Due to Alzheimer’s Disease

Enrollment of First Patients Expected in Q1 2018 Baltimore, MD, September 19, 2017 — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced it has been awarded a grant from the National Institute on Aging (NIA) of the National Institutes of Health (NIH) to support its Phase 3 HOPE4MCI clinical…

AgeneBio to Receive up to $10 Million in NIH Funding to Advance Program for Mild Cognitive Impairment Due to Alzheimer’s Disease

Grant to support novel GABAA program targeting hippocampal overactivity that leads to neurodegeneration and cognitive decline in Alzheimer’s disease patients Baltimore, MD, September 13, 2017 — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced it has been awarded a grant for up to $10 million from the National Institute…